New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq

NEXT STORY
Site Management Organizations Market by Therapeutic Areas, Trial Phases, Clinical Trial Components, Type of Interventions and Key Geographies : Industry Trends and Global Forecasts, 2021-2035
PREV STORY
First subject dosed in phase I clinical study with eye-drop formulation of laquinimod  
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Heat Biologics to Present at the 28th Annual ROTH Conference

DURHAM, N.C., March 04, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an ...

author_avatar
NASDAQ Market News

Iaslc, 주요 학회들과 공동으로 폐암에 대한 분자 테스트와 표적 치료법 가이드라인 개정안 공개

미국 덴버, Jan. 25, 2018 (GLOBE NEWSWIRE) -- 폐암에 대한 분자진단 검사가 발전을 거듭함에 ...

author_avatar
NASDAQ Market News

Capital Digestive Care Welcomes Two New Healthcare Professionals

Chevy Chase, MD, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Capital Digestive Care has tapped ...

author_avatar
NASDAQ Market News